Provide update on immuno-oncology phase I basket study
Delivered after the deadline (20 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- 20 Jul 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“provide the next update on its immuno-oncology phase I basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021”
What we found
Evidence strength A What the grades mean
The company provided an update on the Study 1100 immuno-oncology basket trial on July 20, 2021, which occurred after the second quarter 2021 deadline.
-
A Nanobiotix S.A. 6-K filed 2021-07-20
“Updated data from Study 1100, a phase I basket study evaluating NBTXR3 activated by radiotherapy (RT) in combination with nivolumab or pembrolizumab... showed tumor regression in 76.9% of evaluable patients” ✓ confirmed on the page
Market reaction: the shares moved -7.3% against the S&P 500 over the three sessions around the disclosure (19 Jul 2021 to 22 Jul 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Provide
- Deliverable
- Phase I basket study update
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Nanobiotix S.A.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-NBTX-021365 · Corrections policy